Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

Background & Aims: Immunotherapy with atezolizumab and bevacizumab (a + b) has improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the outcome for individual patients is highly variable. This study aimed to (i) develop and validate a prognostic predictio...

Descripción completa

Detalles Bibliográficos

Autores principales:	Simon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, Fabian Artusa, Bernhard Scheiner, Catherine Leyh, Sabine Lieb, Friedrich Sinner, Vincent Jörg, Thorben Fruendt, Vera Himmelsbach, Nada Abedin, Cennet Sahin, Katrin Böttcher, Jasmin Schuhbaur, Simon Labuhn, James Korolewicz, Claudia A.M. Fulgenzi, Antonio D'Alessio, Valentina Zanuso, Florian Hucke, Natascha Röhlen, Najib Ben Khaled, Eleonora Ramadori, Lukas Müller, Arndt Weinmann, Roman Kloeckner, Peter Robert Galle, Nguyen H. Tran, Sudhakar K. Venkatesh, Andreas Teufel, Matthias Ebert, Enrico N. De Toni, Dirk-Thomas Waldschmidt, Jens U. Marquardt, Dominik Bettinger, Markus Peck-Radosavljevic, Andreas Geier, Florian P. Reiter, Lorenza Rimassa, David J. Pinato, Christoph Roderburg, Thomas Ettrich, Michael Bitzer, Veit Scheble, Ursula Ehmer, Marie-Luise Berres, Fabian Finkelmeier, Maria Angeles Gonzalez-Carmona, Johann von Felden, Kornelius Schulze, Marino Venerito, Florian van Bömmel, Leonie S. Jochheim, Matthias Pinter, Raphael Mohr, Sumera I. Ilyas, Irene Schmidtmann, Friedrich Foerster
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2025-03-01
Colección:	JHEP Reports
Materias:	Hepatocellular carcinoma Cirrhosis Systemic therapy Prediction model Outcome PD-L1
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2589555924002994
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!